Gene of the month: cancer testis antigen gene 1b (NY-ESO-1)

The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020

(2023) Viktoria Gloy et al.   INTERNATIONAL JOURNAL OF CANCER

The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines

(2022) Jiao Wei et al.   CANCER TREATMENT REVIEWS

Immunotherapy of sarcomas with modified T cells

(2022) Preethika Mahalingam et al.   CURRENT OPINION IN ONCOLOGY

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

(2022) Alexandra Gyurdieva et al.   Nature Communications

Targeting cancer testis antigens in synovial sarcoma

(2021) Geoffrey Mitchell et al.   Journal for ImmunoTherapy of Cancer

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy

(2020) Afsheen Raza et al.   Journal of Translational Medicine

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

(2020) Jonathan S Cebon et al.   Journal for ImmunoTherapy of Cancer

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

(2020) Ugur Sahin et al.   NATURE

Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses

(2019) Karim Vermaelen   Frontiers in Immunology

1309TiPTrial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumours (IMCnyeso-101)

(2019) J Lopez et al.   ANNALS OF ONCOLOGY

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers

(2018) Ashwini Raghavendra et al.   HISTOPATHOLOGY

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259 T Cells in Synovial Sarcoma

(2018) Sandra P. D'Angelo et al.   Cancer Discovery

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives

(2018) Remy Thomas et al.   Frontiers in Immunology

Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma

(2015) Mara Giavina-Bianchi et al.   Journal of Immunology Research

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma

(2015) Eva Giesen et al.   Oncotarget

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions

(2014) Paul F. Robbins et al.   JOURNAL OF IMMUNOLOGY

NY-ESO-1 (CTAG1B) expression in mesenchymal tumors

(2014) Makoto Endo et al.   MODERN PATHOLOGY

A Potential Role for Immunotherapy in Thyroid Cancer by Enhancing NY-ESO-1 Cancer Antigen Expression

(2014) Viswanath Gunda et al.   THYROID

Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma

(2013) Morten F Gjerstorff et al.   BMC CANCER

NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms

(2013) Jessica A Hemminger et al.   MODERN PATHOLOGY

Centrosomal Localisation of the Cancer/Testis (CT) Antigens NY-ESO-1 and MAGE-C1 Is Regulated by Proteasome Activity in Tumour Cells

(2013) Anna Pagotto et al.   PLoS One

Multiple Cancer Testis Antigens Function To Support Tumor Cell Mitotic Fidelity

(2012) K. M. Cappell et al.   MOLECULAR AND CELLULAR BIOLOGY

HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression

(2012) Pierre-François Cartron et al.   Molecular Oncology

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

(2011) Elisabetta Fratta et al.   Molecular Oncology

Mage-A Cancer/Testis Antigens Inhibit p53 Function by Blocking Its Interaction with Chromatin

(2010) L. Marcar et al.   CANCER RESEARCH

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE